IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$8.88 USD
+0.05 (0.57%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $8.90 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
IGMS 8.88 +0.05(0.57%)
Will IGMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IGMS
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Other News for IGMS
Notable Two Hundred Day Moving Average Cross - IGMS
Commit To Purchase IGM Biosciences At $10, Earn 30.4% Annualized Using Options
RBC says NEJM publication of anti-CD38 mAb approach helps to de-risk IGM's '2644
IGM Biosciences participates in a conference call with JPMorgan
IGM Biosciences Stockholders Endorse Governance and Compensation Plans